BACKGROUND: Throughout the last decade, tuberculosis (TB) treatment success has not surpassed 90%, the global target. The impact of mobile health interventions (MHIs) on TB treatment outcomes is unknown, especially in low- and middle-income countries (LMICs). MHIs, including interactive voice response technology (IVRT), may enhance adherence and retention in the care of patients with tuberculosis and improve TB treatment outcomes. This study seeks to determine the impact of IVRT-based MHI on TB treatment success (treatment completion and cure rates) in patients with TB receiving care at five public health facilities in Uganda. METHODS: We used a theory-based and human-centered design (HCD) to adapt an already piloted software to design "Cal...
Nonadherence to treatment remains an obstacle to tuberculosis (TB) control worldwide. The aim of thi...
Background. Social support has been shown to mitigate social barriers to medication adherence and im...
BackgroundAdherence to and completion of tuberculosis (TB) treatment remain problematic in many high...
Abstract Background Throughout the last decade, tuberculosis (TB) treatment success has not surpasse...
Although tuberculosis is a treatable disease, the high frequency of treatment default remains a chal...
BackgroundTuberculosis (TB) is an urgent global health threat and the world’s deadliest infectious d...
BackgroundPre-treatment loss to follow-up is common for patients diagnosed with tuberculosis (TB) in...
BackgroundTuberculosis (TB) is an urgent global health threat and the world's deadliest infectious d...
Background: Adherence to tuberculosis (TB) treatment is challenging because of many factors. The Wor...
99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-...
Background: Compliance to anti-TB treatment is crucial in achieving cure and avoidi...
Tuberculosis (TB) is global health concern and a leading infectious cause of mortality. Reversing TB...
Digital technologies are increasingly harnessed to support treatment of persons with tuberculosis (T...
Background: The World Health Organization (WHO) recommends the use of mobile health (mHealth) techno...
Tuberculosis (TB) is global health concern and a leading infectious cause of mortality. Reversing TB...
Nonadherence to treatment remains an obstacle to tuberculosis (TB) control worldwide. The aim of thi...
Background. Social support has been shown to mitigate social barriers to medication adherence and im...
BackgroundAdherence to and completion of tuberculosis (TB) treatment remain problematic in many high...
Abstract Background Throughout the last decade, tuberculosis (TB) treatment success has not surpasse...
Although tuberculosis is a treatable disease, the high frequency of treatment default remains a chal...
BackgroundTuberculosis (TB) is an urgent global health threat and the world’s deadliest infectious d...
BackgroundPre-treatment loss to follow-up is common for patients diagnosed with tuberculosis (TB) in...
BackgroundTuberculosis (TB) is an urgent global health threat and the world's deadliest infectious d...
Background: Adherence to tuberculosis (TB) treatment is challenging because of many factors. The Wor...
99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-...
Background: Compliance to anti-TB treatment is crucial in achieving cure and avoidi...
Tuberculosis (TB) is global health concern and a leading infectious cause of mortality. Reversing TB...
Digital technologies are increasingly harnessed to support treatment of persons with tuberculosis (T...
Background: The World Health Organization (WHO) recommends the use of mobile health (mHealth) techno...
Tuberculosis (TB) is global health concern and a leading infectious cause of mortality. Reversing TB...
Nonadherence to treatment remains an obstacle to tuberculosis (TB) control worldwide. The aim of thi...
Background. Social support has been shown to mitigate social barriers to medication adherence and im...
BackgroundAdherence to and completion of tuberculosis (TB) treatment remain problematic in many high...